Category - Markets

Markets

Roth starts LogicBio Therapeutics at buy; PT $26

Roth Capital Partners initiated coverage of LogicBio Therapeutics (NASDAQ:LOGC) with a “buy” rating and $26 price target. The stock closed at $13.61 on April 30.

May 1, 2019

Markets

Mackie starts Medicenna Therapeutics at speculative buy; PT $1.50

Mackie Research launched coverage of Medicenna Therapeutics (TSX:MDNA) with a “speculative buy” rating and a 12-month target price of $1.50. The stock closed at 68 cents on April 29.

April 30, 2019

Markets

Roth starts Zynerba Pharma at buy; PT $36

Roth Capital Partners initiated coverage of Zynerba Pharmaceuticals (NASDAQ:ZYNE) with a “buy” rating and $36 price target. The stock closed at $11.56 on April 29

April 30, 2019

Markets

Roth starts Zafgen at buy; PT $8

Roth Capital Partners launched coverage of Zafgen (NASDAQ:ZFGN) with a “buy” rating and price target of $8. The stock closed at $2.56 on April 25.

April 26, 2019

Markets

SVB Leerink starts Genfit at OP; PT $58

SVB Leerink launched coverage of French-based Genfit (NASDAQ:GNFT) with an “outperform” rating and $58 price target. The stock closed at $25.47 on April 23.

April 24, 2019